Volume 173, Issue 1 pp. 272-274
Research Letter

Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients

B.B. Jones

B.B. Jones

School of Medicine, University of Utah, 30N 1900 East, Salt Lake City, UT, 84132 U.S.A

Search for more papers by this author
J.W. Millsop

J.W. Millsop

University of California, Davis, Department of Dermatology, Sacramento, CA, U.S.A

Search for more papers by this author
J.A. Walsh

J.A. Walsh

Division of Rheumatology, University of Utah, 30N 1900 East, Salt Lake City, UT, 84132 U.S.A

Search for more papers by this author
G.G. Krueger

G.G. Krueger

Department of Dermatology, University of Utah, 30N 1900 East, Salt Lake City, UT, 84132 U.S.A

Search for more papers by this author
K. Callis Duffin

Corresponding Author

K. Callis Duffin

Department of Dermatology, University of Utah, 30N 1900 East, Salt Lake City, UT, 84132 U.S.A

Correspondence: Kristina Callis Duffin.

E-mail: [email protected]

Search for more papers by this author
First published: 30 December 2014
Citations: 24
Funding sources: None.
Conflicts of interest: K.C.D. has served on the scientific and marketing advisory boards of Amgen; served as a consultant to Amgen, Janssen, Pfizer and Eli Lilly receiving honoraria; received payments for lectures from AbbVie, Amgen and Janssen; and served as an investigator for AbbVie, Amgen, Janssen, Pfizer, Eli Lilly and Vascular Biologics Limited. G.G.K. has received fees as a consultant or advisory board member for AbbVie, Amgen, ApoPharma, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Idera, Isis, Janssen, L'Oréal, Novartis, Pfizer, UCB and Vascular Biologics Limited. G.G.K. has also received partial stipend support for a clinical research fellowship from AbbVie, Amgen and Centocor/Janssen, and in the last 12 months has received lecture fees from Abbott, Amgen and Janssen.
First page image

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.